Literature DB >> 24515100

Dosing in children: a critical review of the pharmacokinetic allometric scaling and modelling approaches in paediatric drug development and clinical settings.

Iftekhar Mahmood1.   

Abstract

It should be recognized that children are not small adults, hence dosing in children should not be a 'small adult dose'. A mean population dose in all age groups is just an average dose and not necessarily the best or the correct dose for a given patient. The dose of a drug varies from patient to patient and individual adjustment of the dose is always ideal but is not always practical. Theoretically, dose selection in paediatric drug development or clinical settings can be done by using either body weight or the clearance of a drug. Over the years, a lot of approaches have been suggested for the prediction of drug clearance or dose in paediatrics. Although some proposed methods are useful for the prediction of clearance or dose in children, there remains a high degree of uncertainty in the prediction of drug clearance or dose in children. In particular, the prediction of clearance or dose in an individual patient remains highly erratic. This review takes a critical look at these approaches and highlights the application and limitations of these proposed methods.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24515100     DOI: 10.1007/s40262-014-0134-5

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  110 in total

Review 1.  Knowledge-driven approaches for the guidance of first-in-children dosing.

Authors:  Andrea N Edginton
Journal:  Paediatr Anaesth       Date:  2010-12-03       Impact factor: 2.556

Review 2.  Population pharmacokinetic studies in pediatrics: issues in design and analysis.

Authors:  Bernd Meibohm; Stephanie Läer; John C Panetta; Jeffrey S Barrett
Journal:  AAPS J       Date:  2005-10-05       Impact factor: 4.009

3.  Prediction of cytochrome p450-mediated hepatic drug clearance in neonates, infants and children : how accurate are available scaling methods?

Authors:  Sven Björkman
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

4.  Allometric exponents do not support a universal metabolic allometry.

Authors:  Craig R White; Phillip Cassey; Tim M Blackburn
Journal:  Ecology       Date:  2007-02       Impact factor: 5.499

Review 5.  Percutaneous drug absorption in the newborn: hazards and uses.

Authors:  N Rutter
Journal:  Clin Perinatol       Date:  1987-12       Impact factor: 3.430

6.  The maturation of morphine clearance and metabolism.

Authors:  T I McRorie; A M Lynn; M K Nespeca; K E Opheim; J T Slattery
Journal:  Am J Dis Child       Date:  1992-08

7.  Lack of pediatric drug formulations.

Authors:  M C Nahata
Journal:  Pediatrics       Date:  1999-09       Impact factor: 7.124

8.  The integration of allometry and virtual populations to predict clearance and clearance variability in pediatric populations over the age of 6 years.

Authors:  Andrea N Edginton; Bhavank Shah; Michael Sevestre; Jeremiah D Momper
Journal:  Clin Pharmacokinet       Date:  2013-08       Impact factor: 6.447

9.  Pharmacometrics-based dose selection of levofloxacin as a treatment for postexposure inhalational anthrax in children.

Authors:  Fang Li; Partha Nandy; Shuchean Chien; Gary J Noel; Christoffer W Tornoe
Journal:  Antimicrob Agents Chemother       Date:  2009-10-26       Impact factor: 5.191

10.  Prediction of the distribution volumes of cefazolin and tobramycin in obese children based on physiological pharmacokinetic concepts.

Authors:  R Koshida; E Nakashima; N Taniguchi; A Tsuji; L Z Benet; F Ichimura
Journal:  Pharm Res       Date:  1989-06       Impact factor: 4.200

View more
  41 in total

1.  Population pharmacokinetics of oxcarbazepine and its monohydroxy derivative in epileptic children.

Authors:  Christelle Rodrigues; Catherine Chiron; Elisabeth Rey; Olivier Dulac; Emmanuelle Comets; Gérard Pons; Vincent Jullien
Journal:  Br J Clin Pharmacol       Date:  2017-09-20       Impact factor: 4.335

2.  Population pharmacokinetics of midazolam and its metabolites in overweight and obese adolescents.

Authors:  Anne van Rongen; Janelle D Vaughns; Ganesh S Moorthy; Jeffrey S Barrett; Catherijne A J Knibbe; Johannes N van den Anker
Journal:  Br J Clin Pharmacol       Date:  2015-09-10       Impact factor: 4.335

Review 3.  State-of-the-Art Review on Physiologically Based Pharmacokinetic Modeling in Pediatric Drug Development.

Authors:  Venkata Yellepeddi; Joseph Rower; Xiaoxi Liu; Shaun Kumar; Jahidur Rashid; Catherine M T Sherwin
Journal:  Clin Pharmacokinet       Date:  2019-01       Impact factor: 6.447

4.  Bayesian Estimation of Vancomycin Pharmacokinetics in Obese Children: Matched Case-Control Study.

Authors:  Jennifer Le; Edmund V Capparelli; Uzra Wahid; Yi Shuan S Wu; Gale L Romanowski; Tri M Tran; Austin Nguyen; John S Bradley
Journal:  Clin Ther       Date:  2015-05-29       Impact factor: 3.393

5.  Discontinuities and disruptions in drug dosage guidelines for the paediatric population.

Authors:  Kate M Chitty; Bosco Chan; Camille L Pulanco; Sonya Luu; Oluwaseun Egunsola; Nicholas A Buckley
Journal:  Br J Clin Pharmacol       Date:  2018-02-21       Impact factor: 4.335

6.  Population Pharmacokinetics of Stiripentol in Paediatric Patients with Dravet Syndrome Treated with Stiripentol, Valproate and Clobazam Combination Therapy.

Authors:  Sophie Peigné; Stéphanie Chhun; Michel Tod; Elisabeth Rey; Christelle Rodrigues; Catherine Chiron; Gérard Pons; Vincent Jullien
Journal:  Clin Pharmacokinet       Date:  2018-06       Impact factor: 6.447

Review 7.  Optimizing treatment outcome of first-line anti-tuberculosis drugs: the role of therapeutic drug monitoring.

Authors:  Roger K Verbeeck; Gunar Günther; Dan Kibuule; Christian Hunter; Tim W Rennie
Journal:  Eur J Clin Pharmacol       Date:  2016-06-15       Impact factor: 2.953

Review 8.  Pediatric Dose Selection and Utility of PBPK in Determining Dose.

Authors:  Ian E Templeton; Nicholas S Jones; Luna Musib
Journal:  AAPS J       Date:  2018-02-13       Impact factor: 4.009

9.  Higher Midazolam Clearance in Obese Adolescents Compared with Morbidly Obese Adults.

Authors:  Anne van Rongen; Margreke J E Brill; Janelle D Vaughns; Pyry A J Välitalo; Eric P A van Dongen; Bert van Ramshorst; Jeffrey S Barrett; Johannes N van den Anker; Catherijne A J Knibbe
Journal:  Clin Pharmacokinet       Date:  2018-05       Impact factor: 6.447

10.  Developmental Pharmacokinetics and Age-Appropriate Dosing Design of Milrinone in Neonates and Infants with Acute Kidney Injury Following Cardiac Surgery.

Authors:  Tomoyuki Mizuno; Katja M Gist; Zhiqian Gao; Michael F Wempe; Jeffrey Alten; David S Cooper; Stuart L Goldstein; Alexander A Vinks
Journal:  Clin Pharmacokinet       Date:  2019-06       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.